Ulcerative colitis Medical Services in China

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease (IBD) characterized by diffuse mucosal inflammation and ulceration limited to the colon and rectum. Unlike Crohn’s disease, UC never involves the small intestine and does not exhibit transmural inflammation or skip lesions. The disease typically begins in the rectum and extends proximally in a continuous pattern. Pathogenesis involves a dysregulated immune response to gut microbiota in genetically susceptible individuals—key susceptibility loci include genes within the HLA region, IL23R, and ECM1. Environmental triggers such as antibiotic exposure in early life, Western diet (high in fat and refined sugars), smoking cessation (paradoxically protective in UC vs. harmful in Crohn’s), and urban living contribute to loss of mucosal barrier integrity and aberrant T-cell activation, particularly Th2 and innate lymphoid cell type 2 (ILC2) responses. Epidemiologically, UC has a bimodal incidence peak: first in adolescence/early adulthood (ages 15–30) and second in older adults (ages 50–70). Prevalence in high-income countries ranges from 100 to 200 per 100,000 persons; in China, incidence has risen sharply over the past two decades, now estimated at 1.5–3.0 per 100,000 annually, reflecting rapid urbanization and dietary shifts. Key risk factors include family history (first-degree relative increases risk 4–10 fold), nonsteroidal anti-inflammatory drug (NSAID) use, appendectomy (protective if performed before age 20), and vitamin D deficiency. UC significantly impairs quality of life: patients report fatigue, fecal urgency/incontinence, abdominal pain, and social withdrawal—up to 40% experience clinically significant anxiety or depression. Work absenteeism averages 12–18 days/year during active flares, and long-term complications—including primary sclerosing cholangitis, colorectal dysplasia (risk rises after 8–10 years of disease), and increased colorectal cancer risk—further erode functional status. Nutritional deficiencies (iron, vitamin B12, folate, vitamin D) are common due to chronic blood loss and malabsorption. Early diagnosis via colonoscopy with biopsy, calprotectin testing, and serologic markers (e.g., ASCA-negative/pANCA-positive profile) is critical to guide therapy and prevent irreversible structural damage.

Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Management aims to induce and maintain remission, prevent complications, minimize corticosteroid exposure, and improve quality of life. Treatment strategies are stratified according to disease extent (proctitis, left-sided, or extensive), severity (mild, moderate, or severe), and treatment response history.

Conservative treatment forms the cornerstone of UC management and must be integrated throughout the disease course. Patients are advised to adopt a low-residue, lactose-restricted diet during active flares to reduce mechanical irritation and diarrhea; however, no universal 'UC diet' is evidence-based for long-term maintenance. Nutritional assessment is essential—up to 85% of hospitalized patients exhibit malnutrition, particularly deficiencies in iron, vitamin D, folate, and vitamin B12 due to chronic blood loss, malabsorption, and reduced intake. Enteral nutrition is not routinely recommended for induction in adults (unlike Crohn’s disease), but oral nutritional supplements may support recovery in undernourished individuals. Smoking cessation is strongly encouraged, as tobacco use paradoxically correlates with lower UC incidence and milder disease—but this does not justify smoking due to overwhelming systemic health risks. Stress reduction techniques—including cognitive behavioral therapy and mindfulness-based interventions—are adjunctive tools shown to modestly improve symptom perception and reduce flare frequency, though they do not alter objective inflammatory markers.

Pharmacotherapy is tailored to disease activity and location. For mild-to-moderate distal disease (proctitis or proctosigmoiditis), topical 5-aminosalicylates (5-ASAs)—such as mesalamine enemas (4 g nightly) or suppositories (1 g daily)—achieve remission in >70% of cases with minimal systemic absorption. Oral 5-ASAs (mesalamine, sulfasalazine, olsalazine, balsalazide) remain first-line for mild-to-moderate extensive UC; dosing is weight-based (e.g., mesalamine 2.4–4.8 g/day), with efficacy dependent on adequate adherence and colonic release formulation. Corticosteroids (e.g., prednisone 40–60 mg/day orally or budesonide MMX 9 mg/day) are reserved for moderate-to-severe flares to induce remission—not for maintenance—due to unacceptable long-term toxicity (osteoporosis, diabetes, cataracts, adrenal suppression). In steroid-refractory or steroid-dependent cases, immunomodulators—including thiopurines (azathioprine 2–3 mg/kg/day or 6-mercaptopurine 1–1.5 mg/kg/day) and methotrexate (15–25 mg/week SC)—are used for steroid-sparing maintenance, requiring therapeutic drug monitoring and vigilant surveillance for myelosuppression and infection. Biologic therapies have revolutionized UC care: anti-tumor necrosis factor agents (infliximab, adalimumab, golimumab) are effective for moderate-to-severe UC unresponsive to conventional therapy; vedolizumab (an α4β7 integrin inhibitor) offers gut-selective action with favorable safety; and ustekinumab (anti-IL-12/23) and newer agents like mirikizumab (anti-IL-23p19) and tofacitinib (a JAK1 inhibitor) provide additional mechanistic options. Therapeutic drug monitoring (TDM) of biologics—measuring trough levels and anti-drug antibodies—is increasingly standard to optimize dosing and prevent secondary loss of response.

Surgical treatment is definitive and curative for UC, indicated in cases of acute severe colitis unresponsive to intravenous corticosteroids and rescue therapy (e.g., infliximab or cyclosporine), dysplasia or colorectal cancer, chronic refractory disease impairing growth or development (in pediatric patients), or life-threatening complications including toxic megacolon, perforation, or massive hemorrhage. The gold-standard procedure is total proctocolectomy with ileal pouch-anal anastomosis (IPAA), preserving continence while eliminating disease. Laparoscopic and robotic-assisted approaches are now routine in high-volume centers, reducing postoperative pain, length of stay, and wound complications. Alternative options include total colectomy with end ileostomy for high-risk or elderly patients, or continent ileostomy (Kock pouch) in select cases. Surgery eliminates colorectal cancer risk and obviates lifelong medical therapy, though pouch-related complications (e.g., pouchitis, strictures, fistulae) occur in ~50% over 10 years and require ongoing gastroenterological follow-up.

China offers distinct advantages in UC management, anchored in its integrated healthcare infrastructure and rapidly evolving clinical ecosystem. First, China hosts some of the world’s largest IBD specialty centers—such as Peking Union Medical College Hospital and Ruijin Hospital—where multidisciplinary teams (gastroenterologists, colorectal surgeons, nutritionists, pathologists, and endoscopists) collaborate within unified electronic health records, enabling seamless longitudinal care. Second, China has pioneered cost-effective biosimilar adoption: multiple high-quality infliximab, adalimumab, and vedolizumab biosimilars are approved and reimbursed under the National Reimbursement Drug List (NRDL), reducing biologic therapy costs by up to 60% compared with originators—dramatically improving access. Third, China leads in real-world evidence generation through national IBD registries (e.g., the China IBD Cohort Study), which inform local treatment guidelines reflecting regional epidemiology, microbiome profiles, and pharmacogenomic variations (e.g., higher TPMT variant prevalence influencing thiopurine dosing). Fourth, advanced endoscopic capabilities—including high-definition chromoendoscopy, narrow-band imaging, and AI-assisted dysplasia detection—are widely deployed, enhancing surveillance accuracy. Finally, traditional Chinese medicine (TCM) is integrated judiciously: certain herbal formulations (e.g., Weichang’an) demonstrate adjunctive efficacy in randomized trials for mild-moderate UC when combined with mesalamine, though TCM is never used monotherapy for moderate-severe disease or as replacement for evidence-based biologics or surgery.

Recovery and long-term management emphasize proactive partnership between patient and provider. Patients should undergo annual colonoscopic surveillance starting 8 years after diagnosis for pancolitis or 12–15 years for left-sided disease, with targeted biopsies per SCENIC guidelines. Vaccination status must be optimized pre-immunosuppression (e.g., pneumococcal, influenza, hepatitis B, varicella-zoster); live vaccines are contraindicated during biologic or thiopurine therapy. Bone mineral density screening is recommended every 2–5 years in patients receiving cumulative corticosteroids ≥3 months. Mental health screening for depression and anxiety is integral, given their high prevalence and bidirectional relationship with disease activity. Patients are educated on symptom diaries, early warning signs of flare (e.g., >4 bloody stools/day, nocturnal diarrhea, fever), and prompt escalation pathways. Pregnancy counseling is essential: most UC medications—including 5-ASAs, biologics, and thiopurines—are considered safe during conception and gestation, supporting planned, well-controlled pregnancies. With comprehensive, individualized, and timely intervention, over 90% of UC patients achieve sustained clinical remission, preserve intestinal function, and lead full, productive lives.